Deal snapshot: Ovid expects to report Phase III data for its Angelman syndrome drug during Q4 2020. It calls Angelini an ideal European partner; deal leaves Ovid to focus its efforts and resources on the US.
Who: Ovid Therapeutics and Angelini Pharma
What: Angelini obtains rights in the EU, UK and Russia to Ovid’s Phase III candidate for Angelman syndrome, a rare...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.
